Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.

In recent years, the therapeutic goals in ulcerative colitis (UC) have become increasingly stringent. Histological features seem to be a reliable predictor of disease outcomes after therapy, and histological remission (HR) is the new frontier in the treatment of UC. Here, we first provide a historical perspective before reviewing indexes in the era of biologics; histology as a treatment goal in UC trials; the poor correlation between symptoms, endoscopy, and histology; and the impact of histology on disease outcomes. HR seems to be a promising end point for the treatment of UC because it is typically associated with better outcomes. Two new validated indexes are available to assess histology more accurately in trials, and they may also be applicable to clinical practice. Additional interventional trials are now necessary to establish definitions of HR and its potential for disease modification.

[1]  B. Sands,et al.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. , 2019, The New England journal of medicine.

[2]  L. Peyrin-Biroulet,et al.  Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis. , 2019, Journal of Crohn's & colitis.

[3]  J. Lindsay,et al.  800 – Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib As an Induction Therapy in Adults with Moderately-To-Severely Active Ulcerative Colitis: Data from the U-Achieve Study , 2019, Gastroenterology.

[4]  S. Vermeire,et al.  1006 – Histologic Remission and Mucosal Healing in a Randomized, Placebo-Controlled, Phase 2 Study of Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis , 2019, Gastroenterology.

[5]  N. Harpaz,et al.  Microscopic heterogeneity in ulcerative colitis: implications for microscopic measurement of disease activity , 2019, Gut.

[6]  Siddharth Singh,et al.  P081 HISTOLOGIC HEALING RATES OF MEDICAL THERAPIES FOR ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS , 2019, Inflammatory Bowel Diseases.

[7]  L. Peyrin-Biroulet,et al.  Effects of Ustekinumab Induction Therapy on Endoscopic and Histologic Healing in the UNIFI Phase 3 Study in Ulcerative Colitis , 2019, Zeitschrift für Gastroenterologie.

[8]  S. Targan,et al.  Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI , 2019, Zeitschrift für Gastroenterologie.

[9]  G. D'Haens,et al.  Definitions of response and remission for the Robarts Histopathology Index , 2018, Gut.

[10]  B. Vaughn,et al.  Maintenance Adalimumab Concentrations Are Associated with Biochemical, Endoscopic, and Histologic Remission in Inflammatory Bowel Disease , 2018, Digestive Diseases and Sciences.

[11]  A. Boruvka,et al.  Tu2006 - Etrolizumab Induction Therapy Improves Histologic Outcomes in Anti-TNF-Failed Patients with Ulcerative Colitis: Results from the Hickory Open-Label Induction Cohort , 2018 .

[12]  I. Nagtegaal,et al.  Assessment of Histological Remission in Ulcerative Colitis: Discrepancies Between Daily Practice and Expert Opinion , 2018, Journal of Crohn's & Colitis.

[13]  C. Taxonera,et al.  Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis , 2018, Digestive Diseases and Sciences.

[14]  S. Vermeire,et al.  Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study , 2018, United European gastroenterology journal.

[15]  S. Ng,et al.  Endoscopic and Histological Mucosal Healing in Ulcerative Colitis in the First Year of Diagnosis: Results from a Population-based Inception Cohort from Six Countries in Asia , 2017, Journal of Crohn's & colitis.

[16]  I. Ojanguren,et al.  Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  R. Pinho,et al.  Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[18]  A. O’Connor,et al.  Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. , 2017, Gastrointestinal endoscopy.

[19]  S. Wong,et al.  Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores , 2017, Journal of Crohn's & colitis.

[20]  S. Necozione,et al.  The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine , 2017, Therapeutic advances in gastroenterology.

[21]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[22]  M. Keir,et al.  Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC , 2016, Gut.

[23]  L. Laine,et al.  Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis , 2016, The American Journal of Gastroenterology.

[24]  P. Rutgeerts,et al.  Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC , 2016, Gut.

[25]  G. Macedo,et al.  Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab. , 2016, Journal of Crohn's & colitis.

[26]  S. Vermeire,et al.  Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. , 2016, The New England journal of medicine.

[27]  A. Cheifetz,et al.  Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study , 2016, The American Journal of Gastroenterology.

[28]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[29]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[30]  L. Peyrin-Biroulet,et al.  Review article: the histological assessment of disease activity in ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[31]  G. D'Haens,et al.  Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[32]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[33]  B. Warren,et al.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up , 2015, Gut.

[34]  S. Travis,et al.  Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.

[35]  Michael Joseph Peterson,et al.  Reproducibility of histological assessments of disease activity in UC , 2014, Gut.

[36]  J. Salleron,et al.  Comparing histological activity indexes in UC , 2014, Gut.

[37]  B. Korelitz,et al.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. , 2014, World journal of gastroenterology.

[38]  M. Vandervoort,et al.  Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.

[39]  S. Nordling,et al.  Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case–control observational study based on registry data , 2014, International journal of cancer.

[40]  D. Rubin,et al.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[41]  A. Griffiths,et al.  Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[42]  A. Cheifetz,et al.  Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[43]  A. Zinsmeister,et al.  Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  P. Rutgeerts,et al.  Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing , 2012, The American Journal of Gastroenterology.

[45]  J. Cotter,et al.  Review of the disease course among adult ulcerative colitis population‐based longitudinal cohorts , 2012, Inflammatory bowel diseases.

[46]  L. Gheorghe,et al.  Endomicroscopy for assessing mucosal healing in patients with ulcerative colitis. , 2011, Journal of gastrointestinal and liver diseases : JGLD.

[47]  D. Franchimont,et al.  Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. , 2011, Journal of Crohn's & colitis.

[48]  B. Korelitz Mucosal healing as an index of colitis activity: back to histological healing for future indices. , 2010, Inflammatory bowel diseases.

[49]  Markus F. Neurath,et al.  New pathophysiological insights and modern treatment of IBD , 2010, Journal of Gastroenterology.

[50]  M. Thabane,et al.  Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[51]  A. Griffiths,et al.  Oral budesonide for induction of remission in ulcerative colitis. , 2010, The Cochrane database of systematic reviews.

[52]  S. Ng,et al.  Therapeutic strategies for the management of ulcerative colitis , 2009, Inflammatory bowel diseases.

[53]  I. Gorelov,et al.  Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial , 2008, Gut.

[54]  N. Harpaz,et al.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.

[55]  R. Petras,et al.  Pathology of inflammatory bowel disease. , 2007, Seminars in pediatric surgery.

[56]  S. Targan,et al.  Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach , 2007, Current opinion in gastroenterology.

[57]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[58]  P. Rutgeerts,et al.  Infliximab Results in Reduction of Inflammation and Inflammatory Markers in the Mucosa of Ulcerative Colitis Patients: The ACT 1 Trial , 2005 .

[59]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[60]  C. Fiocchi,et al.  Adequacy of mucosal biopsies for evaluation of intestinal cytokine-specific mRNA , 1995, Digestive Diseases and Sciences.

[61]  Alastair Forbes,et al.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. , 2004, Gastroenterology.

[62]  I. S. Shaw,et al.  Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[63]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.

[64]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[65]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[66]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[67]  B. Korelitz,et al.  Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. , 1975, The American journal of gastroenterology.

[68]  A. Dick,et al.  Persistence of mucosal abnormality in ulcerative colitis. , 1966, Gut.

[69]  A. Dick,et al.  Ulcerative Colitis , 1961 .

[70]  S. Truelove,et al.  Cortisone and Corticotrophin in Ulcerative Colitis , 1959, British medical journal.

[71]  S. Truelove,et al.  Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.